The Centers for Medicare & Medicaid Services (CMS) has officially released the final rate announcement for the 2027 Medicare Advantage (MA) and Part D plan year. In a move that has caught the attention of health insurers and policy analysts alike, the agency finalized a 2.48% net increase in payments to MA plans. This represents a significant upward shift from the near-zero “flat” rate initially proposed in the Advance Notice earlier this year, signaling a more moderate approach to program sustainability and insurer compensation.
Breaking Down the 2027 Final Rule: The $13 Billion Shift
The 2027 final rule is projected to funnel an additional $13.8 billion into the Medicare Advantage program compared to 2026. While the headline figure is 2.48%, the total expected growth in revenue—when accounting for “coding trend” (the way plans document the health status of their members)—is estimated to be closer to 4.98%.
Key Financial Drivers of the 2.48% Increase
To understand how CMS arrived at this percentage, we must look at the specific components that adjust the baseline payments:
The most dramatic change from the initial proposal was the Effective Growth Rate, which jumped from a proposed 4.97% to a finalized 5.33%. This reflects updated data showing higher-than-expected medical utilization and rising costs within the “Original Medicare” (Fee-for-Service) sector, which serves as the benchmark for MA payments.
The Risk Adjustment Battle: CMS Blinks on Major Model Changes
One of the most contentious points of the 2027 proposal was the planned overhaul of the risk adjustment model. CMS had initially suggested a more aggressive move to a newer version of its Hierarchical Condition Category (HCC) model. However, in the final rule, the agency chose to maintain the 2024 MA risk adjustment model for the 2027 plan year.
Why This Matters
Risk adjustment is the mechanism by which CMS pays plans more for sicker patients. When CMS updates these models, it often results in “negative” adjustments to the base rate because the new models are more “accurate” at filtering out over-coding. By sticking to the 2024 model, CMS provided a level of predictability that many insurers were lobbying for, fearing that a sudden shift would lead to benefit cuts for seniors.
The “Unlinked” Chart Review Crackdown
Despite the model freeze, CMS did not back down on one critical integrity measure: the exclusion of unlinked chart reviews.
The Rule: Starting in 2027, CMS will no longer accept diagnosis codes that are found in medical records but are not tied to a specific, documented patient visit (encounter).
The Impact: This is a direct hit to “retrospective” risk adjustment, where plans hire vendors to scrub old charts for missed diagnoses to boost payments. CMS estimates this will have a -1.53% impact on total payments.
Implications for Insurers and Beneficiaries
For Health Insurance Giants (UnitedHealth, Humana, CVS Health)
The 2.48% increase is a “breather” for the industry. Earlier in the year, when the 0.09% proposal was announced, health insurance stocks saw significant volatility. The industry argued that a flat rate, combined with medical inflation and the phase-in of previous cuts, would force them to reduce supplemental benefits like dental, vision, and gym memberships.
With a 2.48% base increase (and a ~5% total revenue trend), many analysts believe most large insurers will be able to maintain stable benefit packages for the 2027 enrollment season, though “benefit rich” plans may still see slight premium increases or higher out-of-pocket maximums to offset the unlinked chart review losses.
For Part D (Prescription Drugs)
The 2027 plan year continues the implementation of the Inflation Reduction Act (IRA). CMS has finalized updates to the Part D risk adjustment model to account for the $2,000 out-of-pocket cap for seniors. Importantly, CMS is now separately accounting for costs in “Standalone” Part D plans versus “Medicare Advantage-Prescription Drug” (MA-PD) plans to improve payment accuracy as the drug market shifts.
Strategic Shift: Quality Over Intensity
CMS Administrator Dr. Mehmet Oz emphasized that the 2027 rates are designed to promote “competition based on quality—not on coding practices.” The agency’s long-term goal remains a transition away from paying for “documentation intensity” and toward paying for “patient outcomes.”
While the 2027 rule is more generous than the proposal, the underlying message to the industry is clear: the era of easy revenue growth through aggressive risk-score mining is ending. Plans that invest in actual care coordination and primary care engagement will be the winners in this new regulatory environment.
Conclusion: A Balanced Path Forward
The 2027 Medicare Advantage Final Rule represents a middle ground. It provides enough funding to prevent a mass exodus of plans or a collapse in supplemental benefits, while still tightening the screws on “unlinked” data and maintaining the statutory minimum for coding pattern adjustments.
As we head into the 2027 plan year, the focus for insurers will shift from lobbying CMS for better rates to operational efficiency—finding ways to manage rising medical costs while their ability to “find” extra risk scores is systematically curtailed.
Frequently Asked Questions (FAQ)
1. Why did CMS increase the rate from the initial proposal?
The increase from 0.09% to 2.48% was largely driven by updated data on medical spending in the fourth quarter of 2025. This data showed that healthcare costs are rising faster than previously estimated, prompting CMS to raise the “Effective Growth Rate.”
2. Will my Medicare Advantage premiums go up in 2027?
While the 2.48% increase helps, it is still below the “medical trend” (inflation) of roughly 4-6%. Some plans may increase premiums or adjust co-pays, but the final rate makes “drastic” benefit cuts less likely than the initial proposal would have.
3. What are “unlinked chart reviews” and why are they being banned?
Unlinked chart reviews are diagnoses added to a patient’s profile based on a review of their records without a corresponding doctor’s visit. CMS believes these lead to overpayment, as they don’t always represent active conditions being treated.
4. How does the Inflation Reduction Act affect these rates?
The IRA has shifted more of the cost of expensive drugs from seniors to the insurance plans. CMS adjusted the Part D risk model for 2027 to help plans cover these new liabilities, ensuring the $2,000 out-of-pocket cap remains sustainable.
5. When do these changes take effect?
These rates apply to the 2027 plan year. Beneficiaries will see the impact of these changes when they begin shopping for plans during the Open Enrollment Period in late 2026.